Practices and Policies of Clinical Exome Sequencing Providers: Analysis and Implications

Overview

Journal Am J Med Genet A

Specialty Genetics

Date 2013 Apr 24

PMID 23610049

Citations 41

Authors

Seema M Jamal

Joon-Ho Yu

Jessica X Chong

Karin M Dent

Jessie H Conta

Holly K Tabor

Michael J Bamshad

Affiliations

Soon will be listed here.

Abstract

Exome and whole genome sequencing (ES/WGS) offer potential advantages over traditional approaches to diagnostic genetic testing. Consequently, use of ES/WGS in clinical settings is rapidly becoming commonplace. Yet there are myriad moral, ethical, and perhaps legal implications attached to the use of ES and health care professionals and institutions will need to consider these implications in the context of the varied practices and policies of ES service providers. We developed "core elements" of content and procedures for informed consent, data sharing, and results management and a quantitative scale to assess the extent to which research protocols met the standards established by these core elements. We then used these tools to evaluate the practices and policies of each of the 6 U.S. CLIA-certified labs offering clinical ES. Approaches toward informed consent, data sharing, and results return vary widely among ES providers as do the overall potential merits and disadvantages of each, and more importantly, the balance between the two.

Citing Articles

Assessment of the current status of real-world pharmacogenomic testing: informed consent, patient education, and related practices.

Pereira L, Haidar C, Haga S, Cisler A, Hall A, Shukla S Front Pharmacol. 2024; 15:1355412.

PMID: 38410134 PMC: 10895424. DOI: 10.3389/fphar.2024.1355412.

Twist exome capture allows for lower average sequence coverage in clinical exome sequencing.

Yaldiz B, Kucuk E, Hampstead J, Hofste T, Pfundt R, Galbany J Hum Genomics. 2023; 17(1):39.

PMID: 37138343 PMC: 10155375. DOI: 10.1186/s40246-023-00485-5.

Characterizing sensitivity and coverage of clinical WGS as a diagnostic test for genetic disorders.

Sun Y, Liu F, Fan C, Wang Y, Song L, Fang Z BMC Med Genomics. 2021; 14(1):102.

PMID: 33849535 PMC: 8045368. DOI: 10.1186/s12920-021-00948-5.

Views on genomic research result delivery methods and informed consent: a review.

Vears D, Minion J, Roberts S, Cummings J, Machirori M, Murtagh M Per Med. 2021; 18(3):295-310.

PMID: 33822658 PMC: 8242984. DOI: 10.2217/pme-2020-0139.

Identifying and Classifying Tools for Health Policy Ethics Review: A Systematic Search and Review.

Henein M, Ells C Health Care Anal. 2021; 29(1):1-20.

PMID: 33386534 DOI: 10.1007/s10728-020-00422-w.

References

Oliver J, Slashinski M, Wang T, Kelly P, Hilsenbeck S, McGuire A . Balancing the risks and benefits of genomic data sharing: genome research participants' perspectives. Public Health Genomics. 2012; 15(2):106-14. PMC: 3318928. DOI: 10.1159/000334718. View

Ludman E, Fullerton S, Spangler L, Trinidad S, Fujii M, Jarvik G . Glad you asked: participants' opinions of re-consent for dbGap data submission. J Empir Res Hum Res Ethics. 2010; 5(3):9-16. PMC: 3071850. DOI: 10.1525/jer.2010.5.3.9. View

Welch J, Westervelt P, Ding L, Larson D, Klco J, Kulkarni S . Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA. 2011; 305(15):1577-84. PMC: 3156695. DOI: 10.1001/jama.2011.497. View

Levenson D . The tricky matter of secondary genomic findings: ACMG plans to issue recommendations. Am J Med Genet A. 2012; 158A(7):ix-x. DOI: 10.1002/ajmg.a.35521. View

Tabor H, Berkman B, Hull S, Bamshad M . Genomics really gets personal: how exome and whole genome sequencing challenge the ethical framework of human genetics research. Am J Med Genet A. 2011; 155A(12):2916-24. PMC: 4819320. DOI: 10.1002/ajmg.a.34357. View

Bainbridge M, Wiszniewski W, Murdock D, Friedman J, Gonzaga-Jauregui C, Newsham I . Whole-genome sequencing for optimized patient management. Sci Transl Med. 2011; 3(87):87re3. PMC: 3314311. DOI: 10.1126/scitranslmed.3002243. View

Townsend A, Adam S, Birch P, Lohn Z, Rousseau F, Friedman J . "I want to know what's in Pandora's Box": comparing stakeholder perspectives on incidental findings in clinical whole genomic sequencing. Am J Med Genet A. 2012; 158A(10):2519-25. DOI: 10.1002/ajmg.a.35554. View

Lupski J, Reid J, Gonzaga-Jauregui C, Rio Deiros D, Chen D, Nazareth L . Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy. N Engl J Med. 2010; 362(13):1181-91. PMC: 4036802. DOI: 10.1056/NEJMoa0908094. View

Green R, Berg J, Berry G, Biesecker L, Dimmock D, Evans J . Exploring concordance and discordance for return of incidental findings from clinical sequencing. Genet Med. 2012; 14(4):405-10. PMC: 3763716. DOI: 10.1038/gim.2012.21. View

10.

Sharp R . Downsizing genomic medicine: approaching the ethical complexity of whole-genome sequencing by starting small. Genet Med. 2011; 13(3):191-4. DOI: 10.1097/GIM.0b013e31820f603f. View

11.

Christenhusz G, Devriendt K, Vermeesch J, Dierickx K . Why genomics shouldn't get too personal: in favor of filters: Re: invited comment by Holly K. Tabor et al. in American Journal of Medical Genetics Part A Volume 155. Am J Med Genet A. 2012; 158A(10):2641-2. DOI: 10.1002/ajmg.a.35547. View

12.

Hull S, Sharp R, Botkin J, Brown M, Hughes M, Sugarman J . Patients' views on identifiability of samples and informed consent for genetic research. Am J Bioeth. 2008; 8(10):62-70. PMC: 4819322. DOI: 10.1080/15265160802478404. View

13.

Flesch R . A new readability yardstick. J Appl Psychol. 1948; 32(3):221-33. DOI: 10.1037/h0057532. View

14.

Biesecker L, Burke W, Kohane I, Plon S, Zimmern R . Next-generation sequencing in the clinic: are we ready?. Nat Rev Genet. 2012; 13(11):818-24. PMC: 3891793. DOI: 10.1038/nrg3357. View

15.

Worthey E, Mayer A, Syverson G, Helbling D, Bonacci B, Decker B . Making a definitive diagnosis: successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease. Genet Med. 2010; 13(3):255-62. DOI: 10.1097/GIM.0b013e3182088158. View

16.

Ng S, Bigham A, Buckingham K, Hannibal M, McMillin M, Gildersleeve H . Exome sequencing identifies MLL2 mutations as a cause of Kabuki syndrome. Nat Genet. 2010; 42(9):790-3. PMC: 2930028. DOI: 10.1038/ng.646. View

17.

Tennessen J, Bigham A, OConnor T, Fu W, Kenny E, Gravel S . Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science. 2012; 337(6090):64-9. PMC: 3708544. DOI: 10.1126/science.1219240. View

18.

Ng S, Buckingham K, Lee C, Bigham A, Tabor H, Dent K . Exome sequencing identifies the cause of a mendelian disorder. Nat Genet. 2009; 42(1):30-5. PMC: 2847889. DOI: 10.1038/ng.499. View

19.

Bick D, Dimmock D . Whole exome and whole genome sequencing. Curr Opin Pediatr. 2011; 23(6):594-600. DOI: 10.1097/MOP.0b013e32834b20ec. View

20.

Bamshad M, Shendure J, Valle D, Hamosh A, Lupski J, Gibbs R . The Centers for Mendelian Genomics: a new large-scale initiative to identify the genes underlying rare Mendelian conditions. Am J Med Genet A. 2012; 158A(7):1523-5. PMC: 3702263. DOI: 10.1002/ajmg.a.35470. View